Cirius Therapeutics puts CIR-0602K in the spotlight as ADA 2026 turns to metabolic complexity

Cirius Therapeutics is pushing CIR-0602K into the ADA 2026 spotlight. Find out why insulin sensitivity may be diabetes’ next battleground.

Cirius Therapeutics is pushing CIR-0602K into the ADA 2026 spotlight. Find out why insulin sensitivity may be diabetes’ next battleground.